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Abstract 
Background: 
The ameloblastic carcinoma is a rare malignant odontogenic tumor which rather occurs in the 
mandible than in the maxilla. Its rarity and in this context somewhat speculative 
histopathogenesis may account for diagnostic difficulties. Current classifications do not 
consider benign histopathological features at the primary and malignant features at the 
metastatic tumour site. Based on an evidence-based literature review, a recommendation for a 
novel classification is presented. 
Methods: 
An evidence-based literature review over the last 60 years regarding ameloblastic carcinoma 
of the maxilla was conducted.  
Results: 
An overall of 26 cases were found (mean age: 54.4 (5-83years); male to female ratio: 2.7 to 
1). In 54% the primary diagnosis was ameloblastic carcinoma, 34.6% revealed pulmonary 
metastases, however, only in one patient cervical lymph node metastasis could be found. 
Whereas two cases did not reveal malignant histopathology at the primary, they revealed 
malignant features at their metastatic sites. Nineteen of 26 patients (73,1%) were controlled 
during a median follow-up time of 54,3 months (6 to 156 months); 6 patients died of disease 
after a median time of 62,7 months (7 to 156 months) after initial diagnosis. 
Conclusion: 
It is of utmost importance to be aware of that ameloblastomas may be capable to degenerate 
into a “malignant” disease with recurrence and metastasis. In addition to local long-term 
control, special attention should be paid to potential pulmonary involvement. 
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Introduction 
Ameloblastomas, representing 1% of all jaw tumours, are considered to be benign, but locally 
aggressive odontogenic epithelial neoplasms [1]. The largest review was performed in 1995 
by Reichart et al [1] comprising 3677 cases. Amongst others, calcifying epithelial 
odontogenic tumor, metastatic carcinoma of the jaw and keratocystic odontogenous tumours 
may come into consideration as differential diagnoses. 
The maxillary mandibular ratio of ameloblastoma is 5 to 1, in favour for the mandible. Its 
most common site of occurrence is the mandibular molar region [1, 2]. More than 50% of 
recurrence appears within the first 5 years after primary surgery[1]. Even though 
ameloblastomas are well studied and documented, little is known about their malignant 
features. This is reflected in the fact that whereas more than 3600 cases of ameloblastomas 
have been described in the literature [3], fewer than 60 cases of ameloblastic carcinoma have 
been reported, among which two thirds occurred in the mandible.  
In regard to malignancy, one must be aware of the difference between malignant 
ameloblastoma and ameloblastic carcinoma. The latter reveals malignant histopathological 
features independent of the presence of metastasis [4], whereas malignant ameloblastomas 
metastasize as well differentiated benign cells [5]. To a high percentage (70-85%) metastases 
of ameloblastoma occur in the lungs [6, 7]. 
Both aetiology of this rare carcinoma and the question whether this type of carcinoma 
originates from an ameloblastoma or represents a separate entity are still controversially 
discussed. However, most of the published data involving ameloblastic carcinoma of the 
maxilla result from single-case reports; prospective data or data from multi-centre studies are 
lacking. Treatment guidelines lack of results from long-term follow-up, because most case 
reports cover a time-span less than 5 years after the primary operation. Moreover, often a 
long-term follow-up is not possible due to advanced age of patients. 
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In comparison to ameloblastic carcinomas of the mandible, maxillary ameloblastic 
carcinomas have not been well studied because of the lack of available data.  
Therefore the aim of the here presented evidence based literature review is to collect clinical 
features and treatment results of maxillary ameloblastic carcinoma over a period of 60 years 
in order to implement a novel classification for this type of carcinoma. 
 
 
Methods 
Electronic databases (Medline and Cochrane) were searched using a set of predetermined 
keywords. The search strategy was initially developed and implemented for PubMed but 
revised appropriately to suite the other database. A combination of free text terms with 
Boolean operators and truncation were used. No restriction was placed on the year or 
language of publication. The search strategy was devised in consultation with a senior 
librarian. 
The citations retrieved from each database were exported into the EndNote bibliometric 
management software. Duplicates were discarded. The titles and abstracts were screened and 
the hard copies of all potentially relevant articles were retrieved. Their reference lists were 
manually searched for any related articles.  
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Results 
During 60 years (1948 – 2008), an overall of 26 cases of maxillary ameloblastic carcinomas 
have been described (Table 1) [8-28]. In 3 cases only, a description of the autopsy result could 
be obtained. The mean age was 54.4 years with a marked prevalence in the group from 41 
years to 80 years (69.2%) (Fig.1); female to male ratio was 1 to 2.7. The predominant chief 
complaint was swelling (Fig. 2). Regarding the tumour localisation, 44% were found in the 
left maxilla, and 32% in the right side of maxilla (Fig. 3); in 54% the first specimen revealed 
directly an ameloblastic carcinoma, but in 15% a follicular ameloblastoma was first found 
(Fig. 4). 26,9% revealed pulmonary metastases and in 23% local recurrence was detected 
(Fig. 5). 77% of the patients underwent a median follow-up period of 54.3 months (6 – 156 
months) while 23% died of disease after a median time of 62,7 (7 months-10 years) months 
after initial diagnosis (Fig. 5). 
 
 
  
Discussion 
Maxillary ameloblastic carcinomas are very rare. Therefore features like metastasis pattern, 
histopathological factors, and gender predilection - in contrary to amelobalstic carcinomas of 
the mandible - have only been presented in single case reports. Hence the intention of this 
study was to collect aspects of clinical appearance and to compare these results with the 
current classifications of ameloblastic carcinomas. Whereas some authors state no gender 
predilection in ameloblastomas [2], a preponderance of males was found in the here presented 
study with a female-male ratio of 1 to 2.7. The first clinical sign in 61.5% of cases was 
swelling; bleeding, ulceration or fistula was only found in 15.4%. It might be assumed that 
therefore patients presented already with a progressive form at first sight. 
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Progressive types of ameloblastic carcinomas may also be associated with the degree of 
aggressiveness being possibly defined as cortical bone perforation, invasion of soft tissue, 
recurrences, and metastases. Both pathways haematogenous as well as lymphatic seem to be 
possible, even though the latter is rare. Among the reviewed cases, 34.6% revealed metastases 
and 23.1% local recurrences. In only one case neck lymph nodes were involved. In 26.9 % 
pulmonary metastases occurred. This high percentage emphasizes the importance to detect 
pulmonary metastases either by computertomography or PET-scans as well as the need for 
long-term follow-up. Besides these screening methods, increasing serum calcium has been 
considered to be a predictor of metastases [12], even though such an increase might be 
unspecific due to an osteolysis.  
Histopathologically two factors have been discussed as predictors for metastasis and/or 
aggressive behaviour: granular cell change; an extensive clear cell component [15, 29, 30]. 
However, these histopathological features have not been investigated in all case reports and 
therefore general interpretation is lacking evidence. The difficulty for this seems to be the 
difference whether the carcinoma is a different entity or whether it has originated from an 
ameloblastoma. 
In the present study (Fig. 4) 50% was determined to be an ameloblastic carcinoma, not 
excluding, however, the potential development of an undetected ameloblastoma. Especially 
this problem has not been considered in current classifications (Table 2). Besides the 
classification of the WHO [31] , two other current classifications have been developed (Table 
1) so far. A significant disadvantage, however, remains the presupposition that the origin, 
including the histopathogenesis of ameloblastic carcinoma, is still unknown. 
 
Therefore, considering its unknown origin and the phenomenon that has been described in the 
literature [8, 10], we recommend a modification of the current classification (Table 2), where 
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a primary ameloblastoma is followed by secondary metastasis with histopathological features 
of malignancy and without evidence of malignancy in the primary localization.  
What treatment armamentarium do we have when dealing with this entity? It is well accepted 
that maxillary ameloblastomas should be treated as radically as possible due to the spongy 
maxillary bone architecture. This structure may facilitate the spread of the tumour and may 
lead to infiltration of adjacent vital structures. In contrast to this, the speed of growth in the 
mandible is decelerated due to the thick and compact bone structure [3].  
Curettage of maxillary ameloblastomas is known to be associated with recurrence in almost 
100% of cases [7]. A surgical resection with 10-15mm margin free of tumour is recommended 
[34], even though the extent of the resection may be limited related to adjacent pivotal 
anatomical structures, particularly in the maxilla. Especially in these kinds of localisations it 
is of utmost importance to be as radical as possible to control recurrence and potential 
degeneration into ameloblastic carcinoma. Regular follow-up and CT- or MRI controls, in 
particular in maxillary ameloblastomas, are broadly accepted among clinicians. 
Controversy still exists regarding its treatment: some authors have suggested radiotherapy [5, 
20, 21] while others [35, 36] doubt its effectiveness. Most of the ameloblastic carcinomas are 
intraosseous; therefore, the effectiveness of radiation therapy must be considered critically. 
Philip et al. (2005) [26] suggested to apply adjuvant radiotherapy in patients with positive 
resection margins, multiple positive lymph nodes, extracapsular spread, perineural invasion, 
and in patients where salvage surgery would be inefficient. Reports about chemotherapy 
regimens in ameloblastic carcinoma are rare. In the present evidence based review only 3 
patients showing a progressive disease were treated with chemotherapy, and (they both ) all of 
them died.  
With respect to aetiology, differentiation from ameloblastomas and an association with 
recurrence relating to multiple surgical procedures have been discussed [33]. Among all the 
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reviewed cases, 27% presented at first histopathologic diagnosis as a follicular or plexiform 
ameloblastoma and secondarily as an ameloblastic carcinoma.  
The lack of non evidence-based study designs represents a major shortcoming of the here 
presented evidence based literature review. This prevents to collect information in a 
standardised manner, however, is in a way to understand due to the rarity of this pathologic 
entity. Considering the limitations of this study, a remarkable aggressiveness of this 
pathologic entity could be detected, even though there were considerable differences in 
respect to the treatment protocols in terms of surgery, postoperative follow-up and period of 
follow-up among the reviewed studies. The authors suggest that in performing multicenter 
studies dealing with such rare entities, it would be easier to develop treatment protocols, 
simply by pooling the cases and experiences of such rare entities. 
To provide more information about the biological behaviour of ameloblastic carcinomas, 
Carinci F et al (2004) [37] described their first genetic portrait. Yet more studies will have to 
be performed before, apart from surgery, specific adjuvant treatment strategies may be 
implemented. This novel classification might be a step on the ladder to specify more 
accurately the original nature of this carcinoma. 
 
 
 
Conclusion 
The novel classification considers the unknown origin as well as primary ameloblastomas 
with metastases and their histopathological features of malignancy without previous evidence 
of malignancy in the primary localization. 
In cases of maxillary ameloblastomas, a radical resection should be performed in order to 
prevent recurrence and development of malignancy. Patients with maxillary ameloblastomas 
should undergo a life-long follow-up including regular CT or MRI scans, for early detection 
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of recurrence. For the staging procedure PET scan or chest CT should be performed in order 
to detect pulmonary metastases. In cases with maxillary ameloblastic carcinoma, a neck 
dissection should only be performed in the presence of clinically positive lymph nodes.  
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Table 1: Overview of published cases of ameloblastic carcinoma of the maxilla in 60 years 
(1948 - 2008) (DF: disease free, nm: not mentioned, DOD: dead of disease) 
Author Year Sex Age treatment metastases Local 
recurrence 
Follow-
up 
(months) 
DOD 
Grimes OF 
[8] 
1948 f 46 Surgical 
excison 
lung  120 NM 
Eda S [9]  1972 f 44 Surgical 
excision 
Submand. 
LN, lung, 
vertebra 
6times 121 DOD 
Krempien 
B [10]  
1979 m 5 Surgical 
excision 
lung  144 DF 
Daramola 
JO [11]  
1980 m 22 Surgical 
excision, 
radiotherapy, 
chemotherapy 
lung  0 NM 
Madiedo G 
[12]  
1981 m 49 Surgical 
excision, 
chemotherapy 
 2times 
(12m,20m) 
60 DOD 
Anderson E 
[13]  
1986 m 73 Surgical 
excision 
 48m 0 NM 
Nadimin H 
[14]  
1987 f 15 Surgical 
excision 
  0 NM 
Corio RL 
[15]  
1987 m 15 Surgical 
excision 
  0 NM 
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Inoue N 
[16]  
1988 f 51 Surgical 
excision 
lung 132m 
recurrence 
0  
McClatchey 
KD [17]  
1989 f 77 Surgical 
excision 
  24 alive 
Lee L [18]  1990 m 56 Surgical 
excision, 
radiotherapy 
lung 5m 7 DOD 
Lolachi CM 
[19]  
1995 f 82 Surgical 
excision 
  0 NM 
Ingram EA 
[20] 
1996 m 83 Surgical 
excision 
  24 alive 
Infante-
Cossio P 
[21] 
1998 f 
 
 
m 
 
m 
69 
 
 
77 
 
64 
Surgical 
excision, 
radiotherpay 
Surgical 
excision 
Surgical 
excision, 
radiotherapy 
 
 
 
brain 
 60 
 
 
7 
 
36 
alive 
 
 
DOD 
 
alive 
Sastre J 
[22] 
2002 m 40 Surgical 
excision 
  24 alive 
Avon SL 
[23]  
2003 m 68 Surgical 
excision 
no no 120 alive 
Zwahlen 
RA [24] 
2003 m 44 Surgical 
excison, 
Cardial, 
pulmonal, 
2times 156 DOD 
 16 
 
Radiotherapy, 
Chemotherapy 
(palliative) 
cerebral 
Dhir K [5]  2003 m 72 Surgical 
excision 
  20 alive 
Goldenberg 
D [25]  
2004 m 72 Surgical 
excision, 
radiotherapy 
   NM 
Philip MP 
[26] 
2005 m 
 
 
m 
70 
 
 
56 
Surgical 
excision, 
Radiotherapy 
Surgical 
excison, 
radiotherapy 
  40 
 
 
8 
Alive 
 
 
alive 
Yazici N 
[27] 
2006 m 10 Surgical 
excision 
  6 alive 
Benlyarzid 
A [28]  
2007 m 90 Surgical 
excision 
  25 DOD 
Ward BB 
[4]  
2007 m 64 Surgical 
excision 
  30 alive 
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Table 2: Classifications of ameloblastic carcinoma by Elzay (1982) and Slootweg & Müller 
(1984) and the novel classification  
Type Elzay (1982)[32] Slootweg & 
Müller 
(1984)[33] 
Kruse et al.(2009) 
1 Arising from an 
odontogenic cyst 
Primary 
intraosseous 
carcinoma ex 
odontogenic cyst 
Malignant ameloblastoma 
1a - - Metastase with features of an 
ameloblastoma (well differentiated) 
1b - - Metastase with malignant features 
(poorly differentiated) 
2 Arising from an 
ameloblastoma 
 Ameloblastic carcinoma arising from 
an ameloblastoma 
2a Well 
differentiated 
(malignant 
ameloblastoma) 
Malignant 
ameloblastoma 
Without metastase 
2b Poorly 
differentiated 
(ameloblastic 
carcinoma) 
Ameloblastic 
carcinoma, 
arising de novo, 
ex 
ameloblastoma or 
ex odontogenic 
cyst 
Metastase with features of an 
ameloblastoma (well differentiated) 
2c   Metastase with malignant features 
(poorly differentiated) 
3 Arising de novo Primary 
intraosseous 
carcinoma de 
novo 
Ameloblastic carcinoma with 
unknown origin histology 
3a No keratinizing No keratinizing Without metastase 
3b Keratinizing Keratinizing Metastase with features of an 
ameloblastoma (well differentiated) 
3c   Metastase with malignant features 
(poorly differentiated) 
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Figure legends 
Fig. 1: Age distribution showing the occurrence of maxillary ameloblastic carcinoma 
Fig. 2: Distribution of first symptoms 
Fig. 3: Distribution of primary tumor localisation  
Fig. 4: Histopathological diagnosis of the first specimen 
Fig. 5: Time (months) of  local recurrence (red) and metastases (blue) appeared 
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